J. Hamilton

发表

Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi[S]

R. Krauss, A. Butler, P. Havel, 2020, Journal of Lipid Research.

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

M. Biermer, N. Goeyvaerts, W. Talloen, 2022, Antiviral therapy.

Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference[S]

R. Krauss, P. Sethupathy, A. Butler, 2019, Journal of Lipid Research.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Manfred von der Ohe, A. Coates, C. Trautwein, 2019, The Lancet.

Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.

S. Kanner, D. Lewis, V. Subbotin, 2020, JCI insight.

RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects

S. Melquist, J. Knowles, P. Clifton, 2019 .

Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.

A. Turner, J. Stoller, R. Bals, 2018, Journal of hepatology.

Hepatic-targeted RNA interference provides persistent knockdown of alpha-1 antitrypsin levels in ZZ patients

A. Turner, J. Stoller, R. Bals, 2018 .

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

S. Melquist, J. Knowles, P. Clifton, 2020 .

Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.

M. Biermer, M. Yuen, D. Wong, 2022, Journal of hepatology.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

S. Kanner, M. Yuen, D. Lewis, 2017, Science Translational Medicine.

PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold

M. Yuen, D. Wong, R. Gish, 2019, Journal of Hepatology.

Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia

S. Melquist, J. Knowles, D. Gaudet, 2020 .

Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE)

Darren H. Wakefield, S. Melquist, D. Lewis, 2016 .

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.

B. Neuschwander‐Tetri, K. Cusi, M. Yuen, 2022, Journal of hepatology.

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

M. Manns, M. Yuen, R. Gish, 2020, Hepatology.

Reduced Expression of Angiopoietin-Like Protein 3 via RNA Interference with ARO-ANG3 Produces Prolonged Reductions in LDL-C and Triglycerides in Dyslipidemic Patients

S. Melquist, J. Knowles, D. Gaudet, 2020 .

Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia

S. Melquist, J. Knowles, D. Gaudet, 2020 .

A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population

R. Gish, J. Lau, T. Schluep, 2017 .

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

M. Yuen, R. Gish, J. Lau, 2017 .

Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

M. Yuen, R. Gish, R. Hammond, 2016 .

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

D. Lewis, R. Gish, T. Schluep, 2016, Clinical pharmacology in drug development.

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

M. Yuen, D. Wong, R. Gish, 2021, Gut.

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

M. Yuen, R. Gish, J. Lau, 2018 .

Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment

M. Biermer, Wei Cheng, R. Gish, 2020, Journal of Hepatology.

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

S. Melquist, J. Knowles, D. Gaudet, 2023, Nature Medicine.

Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520

M. Yuen, R. Gish, J. Lau, 2016 .

Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.

A. Turner, J. Stoller, R. Bals, 2018, Journal of hepatology.